Author:
Pacchioni M.,Camisasca R.,Caminiti M.,Andreotti A. C.,Pontiroli A. E.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference9 articles.
1. Cannavò S., Curtò L., Squadrito S., Almoto B., Vieni A., Trimarchi F. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J. Endocrinol. Invest. 1999, 22: 354–359.
2. Pontiroli A.E., Cammelli L., Baroldi P., Pozza G. Inhibition of basal and metoclopramide-induced pro-lactin release by cabergoline, an extremely long-acting dopaminergic drug. J. Clin. Endocrinol. Metab. 1987, 65: 1057–1059.
3. Andreotti A.C., Pianezzola E., Persiani S., Pacciarini M.A., Strolin Benedetti M., Pontiroli A.E. Pharmacokinetics, pharmacodynamics, and tolera-bility of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0 and 1.5 milligrams) in healthy male volunteers. J. Clin. Endocrinol. Metab. 1995, 80: 841–845.
4. Rains C., Bryson H.M., Fitton A. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and suppression of lactation. Drugs 1995, 49: 255–271.
5. Ferrari C., Paracchi A., Romano C., Gerevini G., Boghen M., Barreca A., Fortini P., Dubini A. Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin. Endocrinol. 1998, 29: 467–476.